Theralase Technologies (TSE:TLT) has released an update.
Theralase Technologies Inc., a company focused on developing treatments for cancer and other diseases, has published its unaudited financial results for the first half of 2024, showing a decline in total revenue by 35% and a net loss reduction of 6%. A conference call to discuss these results is scheduled for August 21, 2024.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.
